Andrew Willan PhD-Biostatistics, MSc-Statistics, BEd-Math and PHE, BA-Economics and Math
- Email Address(es)
- Office Phone
- Office Address
- Program in Child Health Evaluative Sciences/SickKids Research Institute 686 Bay Street, Room 11.9708 Toronto, ON M5G 1E2
- Andy Willan's Home Page, Internet Randomization Service
- Curriculum Vitae
- Biostatistics Division
- SGS Status
- Full Member
- Appointment Status
- Status Only
- Clinical trials methodology
- Statistical analysis of cost-effectiveness data
- Expected value of information and optimal design of clinical trials
- Bayesian analysis of randomised clinical trials
Education & Training History
- PhD in Biostatistics from the Department of Epidemiology and Biostatistics at the University of Western Ontario, London ON, 1979.
- MSc in Statistics from Queen’s University, Kingston ON, 1976.
- BEd in Mathematics and Physical Education from Queen’s University, Kingston ON, 1972.
- BA in Economics and Mathematics from York University, Toronto ON, 1970.
Senior Scientist Emeritus
Program in Child Health Evaluative Sciences
SickKids Research Institute
Department of Clinical Epidemiology and Biostatistics
Primary Teaching Responsibilities
- Advanced Statistical Methods for Clinical Trials (CHL 5225 H)
Honours & Awards
Current Research Projects
- Canadian Institutes of Health Research, The Twin Birth Study (200211MCT-110280). Barrett J (Principal Investigator), Willan A, and 7 others. $8,608,045, 2003-2014.
- National Science and Engineering Council, Expected Value of Information and Optimal Trial Design (RGPIN 44868-08). Willan AR (Principal Investigator) $70,000, 2008-2013.
- Canadian Institutes of Health Research, The Bedside Paediatric Early Warning System: a cluster randomized trial of mortality and processes of care. Parshuram C (Principal Investigator),Willan AR, and 13 others. $3,959,716, 2010-2014.
- Canadian Institutes of Health Research, Sustainability of a multidimensional knowledge translation intervention to improve paediatric pain practices and outcomes. Bonnie Stevens (Principal Investigator), Willan AR, and 20 others. $998,061, 2011-2014.
- Bill and Belinda Gates Foundation, Parathyroid-vitamin D axis dysregulation in early-onset infant stunting in resource-poor settings. Dan Roth (Principal Investigator), Willan AR,and 5 others. $1,999,993, 2012-2016.
- Canadian Institutes of Health Research,Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial. Stephen Freedman (Principal Investigator), Willan AR, and 9 others. $2,231,300, 2013-2018.
- Canadian Institutes of Health Research, Sucrose Practices for Pain in Neonates (SPiN); A Program of Research. Bonnie Stevens (Principal Investigator),Willan AR, and 12 others. $1,246,500, 2013-2018.
- Willan AR. Accounting for treatment by center interaction in sample size determinations and the use of surrogate outcomes in the pessary for the prevention of preterm birth trial: a simulation study. BMC Trials 2016 17(1):310.
- Chan KKW, Xie F, Willan AR. Gupta M, Pullenayegum E. Underestimation of variance of predicted health utilities derived from multi-attribute utility instruments: the use of multiple imputation as a possible solution. Medical Decision Making 2016; DOI 1011.77/0272989X16650181.
- Chen MH, Willan AR. Value of information methods for assessing a new diagnostic test. Statistics in Medicine 2014; 33(11):1801-1815.
- Chan KKW, Willan AR, Gupta M, Pullenayegum E. Underestimation of Uncertainties in Health Utilities derived from Mapping Algorithms involving Health Related Quality of Life Measures: Statistical Explanations and Potential Remedies. Medical Decision Making 2014; 34(7):863-872.
- Willan AR. Bayesian decision theory and the design and analysis of randomized clinical trials. In: Development in Statistical Evaluation of Clinical Trials. K. van Montfort, J. Oud und W. Ghidey (ed). Springer-Verlag 2014.
- Willan AR. Bayesian methods provide important advantages for the design, analysis and interpretation of clinical studies. In: Important Considerations for Clinical Trial Methodologies. Future Medicine 2013. doi: 10.4155/9781909453319
- Chen MH, Willan AR. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods. Clinical Trials 2013; 10(1):54–62.
- Eckermann S, Willan AR. Optimal global VOI trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing. PharmacoEconomics 2013; 31(5):393-401,
- Hossain A, Willan AR, Beyene J. A flexible nonparametric approach to find candidate genes associated to disease in microarray experiments. Journal of Bioinformatics and Computational Biology 2013; 11(2):1250021 (19 pages).
- Hossain A, Willan AR, Beyene J. An improved method on Wilcoxon rank sum test for gene selection from microarray experiments. Communications in Statistics 2013; 42(7):1563-1577
- Willan AR, Goeree R, Boutis K. Value of Information methods for planning and analyzing clinical studies optimize decision making and research planning. Journal of Clinical Epidemiology 2012; 65(8):870-876
- Willan AR, Eckermann S. Value of information and pricing new health care interventions. PharmacoEconomics 2012; 30(6):447-459.
- Willan AR, Eckermann S. Accounting for between-study variation in incremental net benefit in value of information methodology. Health Economics 2012; 21(10):1183–1195.
- Pullenayegum EM, Willan AR. Marginal models for censored longitudinal cost data: appropriate working variance matrices in inverse-probability-weighted GEEs can improve precision. The International Journal of Biostatistics 2011; 7(1), Article 14.
- Willan AR. Sample size determination for cost-effectiveness trials. PharmacoEconomics 2011; 29(11):933-949.
- Eckermann S, Willan AR. Presenting and summarizing cost and effect evidence to best inform inference and societal decision making when comparing multiple strategies. PharmacoEconomics 2011; 29(7):563-577.
- Eckermann S, Coory M, Willan AR. Consistently estimating risk difference when translating evidence to jurisdiction of interest. PharmacoEconomics 2011; 29(2):87-96.
- Eckermann S, Karnon J, Willan AR. The value of information: Best informing research design and prioritization using current methods. PharmacoEconomics 2010; 28(9):699-709.
- Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. Health Economics 2010; 19:549-561.
- Hossain A, Beyene J, Willan AR, Hu P. A flexible approximate likelihood ratio test for detecting differential expression in microarray data. Computational Statistics and Data Analysis 2009; 53(10):3685-3695.
- Eckermann S, Coory M, Willan AR. Indirect comparison: relative risk fallacies and odds solution. Journal of Clinical Epidemiology 2009; 62(10): 1031-1036.
- Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Economics 2009; 18(2): 203-216.
- Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. Clinical Trials 2008; 5(6): 587-594.
- Willan AR, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clinical Trials 2008; 5(4): 289-300.